Literature DB >> 28869439

Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.

Jing Chen, Shun-Wang Cao, Zhen Cai, Lei Zheng, Qian Wang.   

Abstract

BACKGROUND: Epithelial-mesenchymal transition (EMT) plays a crucial role in circulating tumor cells (CTCs) dissemination and cancer metastasis.
OBJECTIVE: To investigate the EMT phenotypes of CTCs in hepatocellular carcinoma (HCC) patients and the clinical utility in the early diagnosis of HCC metastasis and progression.
METHODS: We retrospectively analyzed the count and EMT classification of CTCs detected by the CanPatrol® platform in 195 HCC patients. The clinical relevance with other pathological features was statistically evaluated.
RESULTS: CTCs were detected in 95% of the 195 HCC patients with a range of 0-86 CTCs. Total CTCs numbers were correlated with BCLC stages, metastasis and serum AFP levels. The AUC of the ROC curve was 0.861 (95% CI: 0.782-0.940) in discriminating metastatic HCC patients with non-metastatic patients. Epithelial, hybrid and mesenchymal CTCs were found in about 53%, 83% and 57% patients, respectively. The proportion of hybrid and mesenchymal CTCs was associated with ages, BCLC stages, metastasis and AFP levels. Besides, recurrent HCC patients presented higher CTCs count and increased hybrid and mesenchymal CTCs.
CONCLUSIONS: CTCs count and EMT classification are correlated with clinical stages and metastasis of HCC, suggesting that they may be potential markers for the early diagnosis of HCC metastasis and progression.

Entities:  

Keywords:  Circulating tumor cells; cancer metastasis; epithelial-mesenchymal transition; hepatocellular carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28869439     DOI: 10.3233/CBM-170315

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  19 in total

1.  A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.

Authors:  Colin M Court; Shuang Hou; Paul Winograd; Nicholas H Segel; Qingyu Wilda Li; Yazhen Zhu; Saeed Sadeghi; Richard S Finn; Ekambaram Ganapathy; Min Song; Samuel W French; Bita V Naini; Shonan Sho; Fady M Kaldas; Ronald W Busuttil; James S Tomlinson; Hsian-Rong Tseng; Vatche G Agopian
Journal:  Liver Transpl       Date:  2018-07       Impact factor: 5.799

Review 2.  Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma.

Authors:  Pai-Chi Teng; Vatche G Agopian; Ting-Yi Lin; Sungyong You; Yazhen Zhu; Hsian-Rong Tseng; Ju Dong Yang
Journal:  J Gastroenterol Hepatol       Date:  2022-05-16       Impact factor: 4.369

3.  Anti-Metastatic Effect of Gold Nanoparticle-Conjugated Maclura tricuspidata Extract on Human Hepatocellular Carcinoma Cells.

Authors:  Sun Young Park; Beomjin Kim; Zhengwei Cui; Geuntae Park; Young-Whan Choi
Journal:  Int J Nanomedicine       Date:  2020-07-27

Review 4.  Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.

Authors:  Joseph C Ahn; Pai-Chi Teng; Pin-Jung Chen; Edwin Posadas; Hsian-Rong Tseng; Shelly C Lu; Ju Dong Yang
Journal:  Hepatology       Date:  2021-01-18       Impact factor: 17.425

Review 5.  Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.

Authors:  Jie Li; Xu Han; Xiaona Yu; Zongzhen Xu; Guangsheng Yang; Bingqi Liu; Peng Xiu
Journal:  J Exp Clin Cancer Res       Date:  2018-09-03

6.  Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer.

Authors:  Jing Chen; Changsheng Ye; Jianyu Dong; Shunwang Cao; Yanwei Hu; Bo Situ; Xiaoxue Xi; Sihua Qin; Jiasen Xu; Zhen Cai; Lei Zheng; Qian Wang
Journal:  J Transl Med       Date:  2020-02-06       Impact factor: 5.531

Review 7.  The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy.

Authors:  Feiyu Chen; Zhangfeng Zhong; Hor-Yue Tan; Ning Wang; Yibin Feng
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

8.  The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.

Authors:  Bin Yi; Tian Wu; Nan Zhu; Yao Huang; Xiaoyu Yang; Lei Yuan; Yingjun Wu; Xiaofei Liang; Xiaoqing Jiang
Journal:  J Nanobiotechnology       Date:  2021-03-16       Impact factor: 10.435

9.  ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway.

Authors:  Jianwen Liu; Ruiqing Liu; Yuyan Liu; Lupeng Li; Huicun Cao; Jian Liu; Guangshao Cao
Journal:  Cell Cycle       Date:  2021-06-07       Impact factor: 5.173

Review 10.  Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications.

Authors:  Qian Zhang; Yuan Rong; Kezhen Yi; Lanxiang Huang; Ming Chen; Fubing Wang
Journal:  Theranostics       Date:  2020-10-26       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.